Published in
Elsevier, The Breast, (64), p. 100-111, 2022
DOI: 10.1016/j.breast.2022.05.004
Links
Tools
Long term outcome data from the EORTC 75111-10114 ETF/BCG randomized phase II study: Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer, followed by T-DM1 after progression
Journal article published in 2022 by
Hans Wildiers 
,
Thomas Meyskens,
Sandrine Marréaud,
Lissandra Dal Lago,
Peter Vuylsteke ,
Giuseppe Curigliano ,
Simon Waters ,
Barbara Brouwers,
Bart Meulemans,
Berta Sousa ,
Coralie Poncet,
Etienne Brain
,
Thomas Meyskens,
Sandrine Marréaud,
Lissandra Dal Lago,
Peter Vuylsteke ,
Giuseppe Curigliano ,
Simon Waters ,
Barbara Brouwers,
Bart Meulemans,
Berta Sousa ,
Coralie Poncet,
Etienne Brain
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 